valproic acid has been researched along with tubastatin a in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brindisi, M; Brogi, S; Butini, S; Campiani, G; Gemma, S; Saraswati, AP | 1 |
| Alfano, AI; Barone, S; Brindisi, M; Cassese, E; Summa, V | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 review(s) available for valproic acid and tubastatin a
| Article | Year |
|---|---|
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Histone Deacetylase 6; Humans; Signal Transduction | 2022 |
2 other study(ies) available for valproic acid and tubastatin a
| Article | Year |
|---|---|
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
Topics: Animals; Biomarkers; Cell Line; Epigenesis, Genetic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Mice; Protein Processing, Post-Translational; Rare Diseases | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |